Bevacizumab (Avastin): Angiogenesis inhibitor via blocking of VEGF-AAtezolizumab (Tecentriq): Programmed death-ligand 1 (PD-L1) blocking antibody for patients with EGFR or ALK genomic tumor aberrations. This evidence concerns the gene VEGFA and neoplasm.